We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
Read MoreHide Full Article
Key Takeaways
JNJ raises 2026 sales guidance to $101-$101.4 billion and adjusted EPS outlook to $11.05-$11.15.
Innovative Medicine sales grow 7.9%, fueled by TREMFYA and DARZALEX, while MedTech growth lags at 2.5%.
JNJ expects $1.36 in acquisition-related ESP in 2027, targeting double-digit growth by decade-end.
Johnson & Johnson (JNJ - Free Report) used its third-quarter 2026 earnings call to raise the full-year guidance following stronger growth in Innovative Medicine, while management acknowledged continued weakness in parts of the MedTech business.
Executives emphasized accelerating pharmaceutical launches, expanding the innovation pipeline and improving MedTech execution. Management also clarified expectations for 2027, including acquisition-related earnings and its path toward double-digit growth by decade-end.
Quarterly adjusted earnings of $2.59 per share exceeded the Zacks Consensus Estimate of $2.53. Revenues of $25.40 billion fell slightly below the consensus estimate of $25.44 billion.
Johnson & Johnson Price, Consensus and EPS Surprise
Chief financial officer Joseph Wolk raised the company's 2026 reported sales guidance to $101-$101.4 billion, representing 7.4% growth at the midpoint. Adjusted earnings guidance increased to $11.05-$11.15 per share.
Wolk attributed the improvement to year-to-date performance and expectations for the fourth quarter. Management also improved its projected operating margin decline to approximately 60 basis points from 75 basis points.
J&J's Pharmaceutical Portfolio Drives Expansion
CEO Joaquin Duato highlighted Innovative Medicine's 7.9% operational sales growth, supported by oncology, immunology and neuroscience.
TREMFYA sales increased 68.3%, while DARZALEX rose 15.4%. Duato reiterated management's expectation that TREMFYA could become a franchise exceeding $10 billion in annual sales.
ICOTYDE also gained traction, with more than 20,000 patients initiating treatment since launch. During questions from JPMorgan, Innovative Medicine chairman Tom Cavanaugh explained that approximately 60% of patients were previously untreated with systemic therapies, highlighting market expansion.
JNJ Faces Pressure to Restore MedTech Momentum
MedTech delivered 2.5% operational sales growth, below management's expectations. Weakness was concentrated in international cardiovascular and surgery operations, alongside Abiomed.
MedTech chairman Tim Schmid attributed challenges to competitive pressure in pulsed field ablation, China's volume-based procurement policies and disruptions in the Middle East affecting hospital purchasing.
During questioning from Citigroup, Schmid acknowledged the performance shortfall but emphasized stable underlying procedure demand. He identified stronger U.S. growth and new product launches as important factors supporting improvement.
J&J Advances Robotics and Product Innovation
Duato emphasized OTTAVA's FDA authorization as a significant milestone in surgical robotics. The company secured its first commercial customer and continues developing additional procedural indications.
Management expects OTTAVA's revenue contribution to build gradually, potentially becoming a significant component of the surgery portfolio by decade-end.
In cardiovascular, Shockwave achieved 17.2% operational growth. Schmid also highlighted VARIPULSE Pro's European performance, while management anticipates U.S. approval during the fourth quarter.
JNJ Clarifies 2027 Earnings and Growth Assumptions
During questioning from Wells Fargo, Wolk clarified that Firefly Bio and Sail Biomedicines would reduce 2026 adjusted earnings by $0.64 and create approximately $1.36 per share in 2027.
Wolk indicated that underlying earnings growth generally should exceed sales growth, while acknowledging the need to account for these transactions.
Responding to Goldman Sachs, Wolk also clarified that management's double-digit growth objective does not depend on additional acquisitions. Instead, existing investments and portfolio improvements underpin the target.
J&J Maintains Focus on Execution and Growth
Management's commentary reflected confidence in Innovative Medicine alongside greater urgency surrounding MedTech improvement. Duato emphasized the contribution of newer products and the company's expanding pipeline.
Executives also reaffirmed plans to separate DePuy Synthes by mid-2027, with Wolk indicating that a spinoff remains the preferred approach. Further details on 2027 expectations are scheduled for the December enterprise business review.
What JNJ's Zacks Rank and Style Scores Indicate
JNJ currently carries a Zacks Rank #4 (Sell), indicating an unfavorable earnings estimate revision trend. Its Value Score of C reflects average valuation characteristics, while Growth Score of B indicates comparatively favorable growth attributes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Moreover, Momentum Score of F signals weak price momentum. JNJ’s VGM Score of D reflects an unfavorable combination of value, growth and momentum characteristics. These readings do not align with the stronger Zacks Rank and Style Score combinations typically associated with better near-term performance potential.
The Zacks Rank remains sensitive to changes in analysts' earnings estimates and could shift as revisions incorporate the latest quarterly results and management's updated outlook.
View the Zacks #1 Rank List
Image: Bigstock
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
Key Takeaways
Johnson & Johnson (JNJ - Free Report) used its third-quarter 2026 earnings call to raise the full-year guidance following stronger growth in Innovative Medicine, while management acknowledged continued weakness in parts of the MedTech business.
Executives emphasized accelerating pharmaceutical launches, expanding the innovation pipeline and improving MedTech execution. Management also clarified expectations for 2027, including acquisition-related earnings and its path toward double-digit growth by decade-end.
Quarterly adjusted earnings of $2.59 per share exceeded the Zacks Consensus Estimate of $2.53. Revenues of $25.40 billion fell slightly below the consensus estimate of $25.44 billion.
Johnson & Johnson Price, Consensus and EPS Surprise
Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote
JNJ Raises 2026 Outlook Amid Stronger Growth
Chief financial officer Joseph Wolk raised the company's 2026 reported sales guidance to $101-$101.4 billion, representing 7.4% growth at the midpoint. Adjusted earnings guidance increased to $11.05-$11.15 per share.
Wolk attributed the improvement to year-to-date performance and expectations for the fourth quarter. Management also improved its projected operating margin decline to approximately 60 basis points from 75 basis points.
J&J's Pharmaceutical Portfolio Drives Expansion
CEO Joaquin Duato highlighted Innovative Medicine's 7.9% operational sales growth, supported by oncology, immunology and neuroscience.
TREMFYA sales increased 68.3%, while DARZALEX rose 15.4%. Duato reiterated management's expectation that TREMFYA could become a franchise exceeding $10 billion in annual sales.
ICOTYDE also gained traction, with more than 20,000 patients initiating treatment since launch. During questions from JPMorgan, Innovative Medicine chairman Tom Cavanaugh explained that approximately 60% of patients were previously untreated with systemic therapies, highlighting market expansion.
JNJ Faces Pressure to Restore MedTech Momentum
MedTech delivered 2.5% operational sales growth, below management's expectations. Weakness was concentrated in international cardiovascular and surgery operations, alongside Abiomed.
MedTech chairman Tim Schmid attributed challenges to competitive pressure in pulsed field ablation, China's volume-based procurement policies and disruptions in the Middle East affecting hospital purchasing.
During questioning from Citigroup, Schmid acknowledged the performance shortfall but emphasized stable underlying procedure demand. He identified stronger U.S. growth and new product launches as important factors supporting improvement.
J&J Advances Robotics and Product Innovation
Duato emphasized OTTAVA's FDA authorization as a significant milestone in surgical robotics. The company secured its first commercial customer and continues developing additional procedural indications.
Management expects OTTAVA's revenue contribution to build gradually, potentially becoming a significant component of the surgery portfolio by decade-end.
In cardiovascular, Shockwave achieved 17.2% operational growth. Schmid also highlighted VARIPULSE Pro's European performance, while management anticipates U.S. approval during the fourth quarter.
JNJ Clarifies 2027 Earnings and Growth Assumptions
During questioning from Wells Fargo, Wolk clarified that Firefly Bio and Sail Biomedicines would reduce 2026 adjusted earnings by $0.64 and create approximately $1.36 per share in 2027.
Wolk indicated that underlying earnings growth generally should exceed sales growth, while acknowledging the need to account for these transactions.
Responding to Goldman Sachs, Wolk also clarified that management's double-digit growth objective does not depend on additional acquisitions. Instead, existing investments and portfolio improvements underpin the target.
J&J Maintains Focus on Execution and Growth
Management's commentary reflected confidence in Innovative Medicine alongside greater urgency surrounding MedTech improvement. Duato emphasized the contribution of newer products and the company's expanding pipeline.
Executives also reaffirmed plans to separate DePuy Synthes by mid-2027, with Wolk indicating that a spinoff remains the preferred approach. Further details on 2027 expectations are scheduled for the December enterprise business review.
What JNJ's Zacks Rank and Style Scores Indicate
JNJ currently carries a Zacks Rank #4 (Sell), indicating an unfavorable earnings estimate revision trend. Its Value Score of C reflects average valuation characteristics, while Growth Score of B indicates comparatively favorable growth attributes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Moreover, Momentum Score of F signals weak price momentum. JNJ’s VGM Score of D reflects an unfavorable combination of value, growth and momentum characteristics. These readings do not align with the stronger Zacks Rank and Style Score combinations typically associated with better near-term performance potential.
The Zacks Rank remains sensitive to changes in analysts' earnings estimates and could shift as revisions incorporate the latest quarterly results and management's updated outlook.